20 results about "Dc vaccine" patented technology

The present disclosure belongs to the field of biotechnology, and specifically relates to a preparation method for an adenovirus p53 (Ad-p53)-loaded dendritic cell (DC) vaccine. The present disclosure includes steps of peripheral blood collection and peripheral blood mononuclear cell (PBMC) separation, PBMC sorting, DC activation, Ad-P53-transfected DC and DC vaccine preparation. P53 can be expressed on a surface of DC as a tumor-associated antigen (TAA) through DC purification, specific multiplicity of infection (MOI) and infection modes, and the Ad-P53-transfected DC has obvious antigen presentation effect, which can be used as a vaccine to activate T cells to kill tumors.

The invention provides a dendritic cell vaccine for treating bone and soft tissue sarcoma as well as a preparation method and application of the dendritic cell vaccine. The dendritic cell vaccine comprises mature dendritic cells obtained by co-culturing sarcoma cell lysate and immature dendritic cells. The lysates of seven sarcoma cells are used as dendritic cell vaccine antigens, the problem that an existing DC vaccine is single in loaded antigen is solved, antigen presentation and T cell activation are enhanced, wide immune response is excited, immune escape is reduced, and the dendritic cell vaccine is not limited by the type of MHC of a patient, is high in universality and can benefit more patients.

The application belongs to the field of biological pharmacy, and particularly relates to application of a Caerin polypeptide combined with a dendritic cell vaccine in preparation of a drug for treating breast cancer. The application finds that F1 / F3 significantly inhibits proliferation of 4T-1 cells and induces cell death in vitro, significantly inhibits growth of a primary tumor, reduces lung metastasis, and prolongs overall survival in vivo, and inoculation of a DC vaccine loaded with a tumor-related antigen can reduce tumor growth and enhance T cell activation in draining and non-draining lymph nodes. Compared with a vaccine loaded with a whole antigen (DCV1), a DC vaccine (DCV2) combined with F1 / F3 induced 'programmed death antigen' exhibits stronger anti-tumor activity, although TNF-alpha and IL-12 secretion thereof is lower. Therefore, the application combines the F1 / F3 polypeptide with the DCV2 to prepare a drug for treating breast cancer, effectively improves the treatment effect on the tumor, and highlights the importance of a combined immunotherapy strategy.

The invention provides a microvesicle-loaded DC vaccine as well as a preparation method and application thereof, DC is taken as a carrier, microvesicles are loaded, and the DC-loaded microvesicles are derived from hepatoma carcinoma cells Hepa1-6; the preparation method comprises the following steps: (1) culturing liver cancer Hepa1-6 cells, exposing the cells in an ultraviolet environment for irradiation, then collecting cell supernatant, and extracting MPs; (2) obtaining bone marrow single cells, firstly inducing the bone marrow single cells into imDC (imDC), and then inducing the bone marrow single cells into mature DC (mDC); and (3) incubating the DC and the MPs to obtain the DC vaccine loaded by the microvesicles. The invention also discloses an application of the DC vaccine loaded by the microvesicles in preparation of drugs or preparations for treating liver cancer. The DC vaccine loaded by the microvesicles can promote the activation of CD8 + T cells and the killing ability to liver cancer cells. According to the present invention, the liver cancer cells can be specifically killed without damaging other tissues, the specific recognition and killing function of the T cells on the tumor cells can be enhanced, and the tumor immune escape can be easily overcome.

The invention belongs to the technical field of nano biomedicine, and particularly discloses a preparation method of a galangin-loaded bionic nano dendritic cell (DCs) vaccine and application of the galangin-loaded bionic nano dendritic cell (DCs) vaccine in ovarian cancer treatment. The inner core of the vaccine is galangin (GA)-loaded polylactic acid-glycolic acid copolymer (PLGA) nanoparticles, and the shell of the vaccine is formed by coating a DCs film carrying tumor antigens. The nano DC vaccine retains the antigen presentation function of natural DCs, and the GA loaded on the nano DC vaccine can induce tumor cells to generate immunogenic cell death. By means of the design, the vaccine can efficiently load specific tumor-associated antigens, and the homing capacity of the vaccine to lymph nodes and tumor microenvironments is remarkably enhanced. Experiments show that GA-NPs (at) DCV is used for treating subcutaneous tumor and in-situ ovarian cancer mouse models.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The invention relates to the field of biological pharmacy, in particular to a DC vaccine, drug-loaded nanoparticles and a preparation method and application of the DC vaccine and the drug-loaded nanoparticles. The composition provided by the invention comprises 0.1 to 50 mM of a cellular pathway inhibitor, mOVA-loaded LNPs containing a tumor antigen, and 0.01 to 50 [mu] g / mL of a cellular pathway agonist. According to the construction and preparation method of the DC vaccine and drug-loaded PLGA nano-particle co-delivery system, the DC vaccine is combined with the agonist-loaded PLGA nano-particles for use, so that T cells are effectively and specifically activated, and an efficient anti-tumor effect is achieved. The combination mode obviously improves the tumor inhibition effect, and the effect is better than that of separate use.

The invention discloses a DC vaccine and application of the DC vaccine and NKG2D-CAR-T cells combined with the DC vaccine in preparation of drugs for treating tumors and drugs for enhancing the curative effect of the CAR-T cells. According to the combined immunotherapy method for enhancing the curative effect of the CAR-T cells and the application of the combined immunotherapy method, the CAR-T cells are prepared from the NKG2D-CAR expressed on the T cells, the CAR-T cells and the DC vaccine loaded with the tumor antigen RAE1 are co-cultured, the killing and multiplication capacity of the NKG2D-CAR-T cells, the secretion and activation level of cell effector factors and the like are studied, and the CAR-T cells and the DC vaccine loaded with the tumor antigen RAE1 are used for enhancing the curative effect of the CAR-T cells. Therefore, the influence of the DC vaccine on the anti-tumor aspect of the NKG2D-CAR-T cells is evaluated. The invention further provides an osteosarcoma animal model, preparation thereof and application of the osteosarcoma animal model in an in-vivo experiment in which the DC vaccine is combined with NKG2D-CAR-T cells to remarkably improve the tumor killing capacity. The invention also discloses a DC vaccine which can obviously improve the tumor killing ability of NKG2D-CAR-T cells, the activation and proliferation level is obviously improved, and in-vivo research finds that the survival rate of mice is obviously improved, and a very good tumor growth inhibition effect is achieved.

Provided herein are methods and materials for treating cancer (e.g., ovarian cancer) using Th17 DC vaccines, optionally in combination with immune checkpoint inhibitors.

A multi-target DC vaccine based on tumor antigen epitope peptides and its application belong to the field of tumor immunotherapy technology. The vaccine comprises an hr-8 conjugate peptide, an immune adjuvant, a carrier, and an immune memory enhancer. The hr-8 conjugate peptide is a conjugate product formed by chemically linking an hr-8 targeting peptide with at least two different tumor antigen CTL epitope peptides. The immune adjuvant is a combined adjuvant system of the TLR9 agonist CpG ODN and the TLR3 agonist poly(I:C). The carrier is PLGA nanoparticles, and the immune memory enhancer is IL-7 and / or IL-15. This invention utilizes the specific binding of the hr-8 peptide to the DEC-205 receptor on the surface of dendritic cells to achieve efficient synergistic delivery and cross-presentation of multi-target antigens. The combined adjuvant and memory factor significantly enhance CTL activation and promote long-term immune memory formation, giving the multi-target DC vaccine advantages such as strong targeting, broad antigen coverage, and prolonged relapse-free survival.

The application belongs to the technical field of biological medicine, and specifically discloses a method for applying induced pluripotent stem cell-derived exosomes in a DC vaccine. The application provides a preparation method of a tumor vaccine, which comprises the following steps: using induced pluripotent stem cell exosomes to sensitize DC cells to obtain the tumor vaccine. The induced pluripotent stem cell-derived exosomes provided by the application have the characteristics of uniform particle size, low toxicity, good cell compatibility, high yield and the like. The DC vaccine provided by the application has the abilities of tumor treatment, tumor prevention and tumor metastasis inhibition, and has low toxicity, and is a simple, practical and applicable technology and method. The application solves the problems of tumorigenicity, large volume, interception by lung and other tissues, difficulty in being taken up by DC, only tumor prevention ability and the like of the existing induced pluripotent stem cell vaccine, and solves the problem of lack of antigen source in the construction of the DC vaccine.

The invention relates to the technical field of biological medicines, in particular to a method for screening a high-activity dendritic cell vaccine by utilizing CD39 and TIM3, which comprises the step of sorting and / or identifying mature dendritic cells by utilizing biomarkers CD39 and TIM3. According to the invention, CD39 and TIM3 are taken as biomarkers for sorting the mo-DC, the high-activity mo-DC vaccine can be screened out, and experimental results show that the high expression of the biomarkers such as CD11C, HLA-DR and CD197 in the mo-DC vaccine obtained by the method is realized; meanwhile, the experimental result also shows that the T cell proliferation proportion of the CD39 + TIM3 + DC stimulation group is obviously higher than that of the DC stimulation group, which indicates that the DC sorted by the CD39 and TIM3 has strong immune response induction capability and is obviously higher than that of the un-screened moDC-DC group.

The present application relates to the technical field of biomedicine, and relates to the preparation of a dendritic cell vaccine for pancreatic cancer and the use thereof in the preparation of a drug for treating pancreatic cancer. The preparation method comprises the preparation of Panc-1 and AsPC-1 lysates, the preparation of immature dendritic cells, and the preparation of a DC vaccine loaded with the Panc-1 and AsPC-1 lysates.

The present application relates to the technical field of biological medicine, and more particularly to a method for screening high-activity dendritic cell vaccine by using CD39 and TIM3, which comprises the steps of sorting and / or identifying mature dendritic cells by using biomarkers CD39 and TIM3. The present application takes CD39 and TIM3 as biomarkers for sorting mo-DC, and can screen high-activity mo-DC vaccine. Experimental results show that the mo-DC vaccine obtained by using the method has high expression of biomarkers such as CD11C, HLA-DR and CD197. Meanwhile, the experimental results also show that the T cell proliferation ratio of the CD39+TIM3+DC stimulation group is significantly higher than that of the DC stimulation group, indicating that the DC sorted by using CD39 and TIM3 has strong ability to induce immune response, and is significantly higher than the mo-DC group without screening.

The present application relates to a kind of renal cancer therapeutic DC vaccine based on the immune peptide activation of HERV-E protein source and its preparation method, and the preparation method includes the following steps: obtaining immature DC cell;Synthesis HERV-E protein source immune peptide;Immune peptide and immature DC are co-cultured in DC activation culture medium for 1 day to DC maturation.The renal cancer therapeutic DC vaccine obtained by the way of immature DC loaded with HERV-E immune peptide is more stable in character, and has strong anti-tumor capacity, can effectively inhibit the progress of renal cancer.

The present application belongs to the field of medical immunology, and particularly relates to a polypeptide composition specifically binding to HLA-A2 typing and application, the polypeptide composition is selected from one or more polypeptides derived from antigen proteins Survivin, Her2, CEA, hTERT, MAGE-A3, EGFR, gp100 or p53, the polypeptide derived from each antigen protein contains an antigen epitope or a variant of the antigen epitope of each antigen protein.The polypeptide composition is presented and activates specific CD8+ cytotoxic T lymphocytes by loading antigen presenting cells to achieve the targeted toxicity effect on tumor cells.The polypeptide composition of the present application and the tumor vaccine, DC vaccine, pharmaceutical composition derived therefrom can significantly activate immune effector cells, especially T cells, significantly improve the secretion level of the activated related cytokines and the killing level on tumor cells, and have potential clinical value.

The invention provides a DC vaccine for treating melanoma and a preparation method and application thereof, and belongs to the field of biological medicine. It is found for the first time that the treatment effect of cDC1 cells treated by taurochenodeoxycholic acid on melanoma is remarkably enhanced, a cDC1 vaccine treated by taurochenodeoxycholic acid has a stronger CD8 + T cell activation effect, anti-tumor immune response can be started more quickly, a stronger tumor killing effect is generated, and a method for treating melanoma is provided for clinic.

The application discloses a tumor antigen for glioma and application thereof, and belongs to the field of biomedical technology. Based on a novel curative effect marker URGCP, HEATR1 and HCMV screening and verification, effective immunogenic peptide segments are obtained, a trivalent vaccine is prepared, and the trivalent vaccine is verified to enhance the antigen presentation ability of DCs in vitro. After overexpression of HCMV and exploration of a suitable radiation dose, in-vivo experiments are used to verify that the trivalent mixed vaccine promotes DC homing, lymph node activation, tumor-specific T cell generation, establishment of humoral immunity and memory immunity. Finally, a preventive model and a therapeutic model are used to verify that the universal DC vaccine can inhibit tumor progression and has good safety.

The invention belongs to the technical field of vaccines, and particularly relates to a novel application of pseudomonas aeruginosa outer membrane vesicles as a DC vaccine activator. Pseudomonas aeruginosa outer membrane vesicles (OMV) are used as an activator auxiliary antigen of the DC vaccine to enhance the immunogenicity of the DC vaccine and enhance T cell immunity, and the DC vaccine is used for preventing the morbidity of hospital pseudomonas aeruginosa and improving the cure rate of patients. According to the invention, an efficient, safe and lasting T cell vaccine platform is constructed by ingeniously utilizing the natural immune activation characteristic of OMV and the antigen presentation capability of DC cells, and the T cell vaccine platform has innovativeness, scientificity and transformation value, and is expected to become a novel immunotherapy strategy for coping with drug-resistant bacterium infection.